【打印本页】 【下载PDF全文】 【HTML】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 2220次   下载 2575 本文二维码信息
码上扫一扫!
琥珀酸索利那新在控制经尿道膀胱肿瘤电切术后膀胱刺激症状中的价值
李磊12△,曹智1△,许传亮1,韦荣超1,张振声1,孙颖浩1*
0
(1. 第二军医大学长海医院泌尿外科, 上海 200433;
2. 安徽省六安市中医院泌尿外科, 安徽 237006
共同第一作者
*通信作者)
摘要:
目的 探讨索利那新在控制经尿道膀胱肿瘤电切术后膀胱刺激症状中的价值。方法 116例诊断为非肌层浸润性膀胱癌的患者纳入本研究,患者被随机分为试验组和对照组。所有患者均接受经尿道膀胱肿瘤电切术和术后即刻表柔比星灌注治疗;试验组患者于术前6 h和术后连续3 d每天口服索利那新5 mg,对照组患者口服安慰剂;于术后6、12、24、48和72 h分别记录膀胱刺激症状评分。结果 膀胱刺激症状的发生率从93.1%(对照组)下降到67.2%(试验组)(P=0.001);在各个观测时间点对照组膀胱刺激症状的严重性均高于试验组(P<0.05或P<0.01)。结论 索利那新可有效改善经尿道膀胱肿瘤电切术后膀胱刺激症状。
关键词:  索利那新  膀胱肿瘤  手术后并发症  膀胱刺激症状  留置导尿
DOI:10.3724/SP.J.1008.2015.00447
投稿时间:2014-08-25修订日期:2014-10-20
基金项目:
Solifenacin succinate in improving bladder irritative symptoms after transurethral resection of bladder tumors
LI Lei1 2△,CAO Zhi1△,XU Chuan-liang1,WEI Rong-chao1,ZHANG Zhen-sheng1,SUN Ying-hao1*
(1. Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China;
2. Department of Urology, Lu'an Hospital of Traditional Chinese Medicine, Lu'an 237006, Anhui, China
Co-first authors.
*Corresponding author)
Abstract:
Objective To explore the value of solifenacin in managing bladder irritative symptoms after transurethral resection of bladder tumor. Methods A total of 116 patients with the diagnosis of non-muscle invasive bladder carcinoma were enrolled in the present study, and they were randomly allocated into experiment group and control group. All patients received transurethral resection of bladder cancer and immediate postoperative instillation of epirubicin. Patients in the experiment group also received solifenacin 5 mg at 6 h before surgery and once a day after surgery for 3 d, while the patients in the control group received placebo. The incidences and severity of catheter related bladder discomfort were recorded at 6, 12, 24, 48 and 72 h after surgery. Results The incidence rate of bladder irritative symptoms significantly decreased from 93.1% in the control group to 67.2% in the experiment group(P=0.001). Compared with the control group, the severity of bladder irritative symptoms in the experiment group was significantly improved at all time points (P<0.05 or P<0.01). Conclusion Solifenacin is effective for managing bladder irritative symptoms after transurethral resection of bladder tumors.
Key words:  solifenacin  urinary bladder neoplasms, postoperative complications  bladder irritative symptoms  catheterization